3. GlaxoSmithKline - Top 15 R&D Budgets
Who: GlaxoSmithKline
Based: United Kingdom
2006 Pipeline Budget: $7.51 billion (€5.13B)
Pipeline News:
GSK had its share of problems this year as safety concerns took a big bite out of Avandia--a blockbuster diabetes drug--sales. The company also fended off riled investors who've been displeased with GSK's lackluster stock performance. In addition, several big GSK drugs, including Wellbutrin XL, Coreg IR, and Zofran--are facing generic competition. However, over the long term, things don't look so bad. The company has an incredible 33 drugs in Phase III development (three times as many as Pfizer) and could launch as many as 25 new drugs over the next two years. GSK is also ramping up marketing of Alli, Cervarix and Tykreb.
Pending Approval:
> Avandia + simvastatin - Type 2 diabetes
> Hycamtin - small cell lung cancer, second-line therapy (oral formulation
> Globorix - diptheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b disease, Neisseria meningitis groups A & C disease prophylaxis
> Infanrix-IPV/Kinrix - Diptheria, tetanus, pertussis and poliomyelitis prophylaxis
> Flu pre-pandemic H5N1 - Pandemic influenza prophylaxis
> Entereg/Entrareg - Post operative ileus Approvable
> Gepirone ER - major depressive disorder, once-daily
> Lamictal XR - Epilepsy
> ReQuip XR - Restless legs syndrome
> Trexima - Migraine
Phase III Pipeline:
> Coreg CR† + ACE - hypertension
> Avandamet XR - Type 2 diabetes
> Avandia - Type 2 diabetes, Prevention of diabetes
> Dacart - Uncomplicated malaria
> Hycamtin - Ovarian cancer, first-line therapy
> Ofatumumab - Chronic lymphocytic leukaemia (also rheumatoid arthritis), follicular lymphoma
> Pazopanib - Renal cell cancer
> Promacta/Revolade - Long-term idiopathic thrombocytopaenic purpura, short-term idiopathic thrombocytopaenic purpura
> Rezonic/Zunrisa - chemotherapy-induced & postoperative nausea & vomiting (also depression & anxiety)
> Tykerb/Tyverb ErbB-2 and EGFR - breast cancer, breast cancer brain metastases, breast cancer (first-line therapy), head & neck squamous cell carcinomas
> Hib-MenCY-TT - Neisseria meningitis groups C & Y disease & Haemophilus influenzae type b disease prophylaxis
> MenACWY-TT - Neisseria meningitis groups A, C, W and Y disease prophylaxis
> Synflorix - Streptococcus pneumoniae & non-typable Haemophilus influenzae disease prophylaxis for children
> MAGE-A3 - Non-small cell lung cancer
> Avodart - Reduction in the risk of prostate cancer
> Avodart + alpha blocker - benign prostatic hyperplasia
> Belimumab - Systemic lupus erythematosus
> Bosatria - Hypereosinophilic syndrome (also severe asthma & nasal polyposis)
> Entereg/Entrareg - Opioid-induced bowel dysfunction
> 1838262 - Restless legs syndrome
> Lamictal XR - Partial generalised tonic-clonic seizures, once-daily
> Rosiglitazone XR - Alzheimer's disease
Full Pipeline Site: Link
Comments
By Anonymous | Posted 10:37pm | October 31, 2008
I was involved in clinical trial of Tykerb with Xeloda from June/08 to Sept/08 as I prgogressed on 18 treatments of Herceptin. (Her 2+ IBC). I saw progression continue to flare up in last 6 weeks of treatment with the Xeloda & Tykerb- Only to be informed I was being "pulled" from the trial immediately, and I was left with NOTHING-even though oncologist "knew" I was prgressing at a fast rate. Then he tells me "Tykerb is usually good for about a 4 month treatment anyway." That came as a shocker!! Then....I find out from some more research-Tykerb is not recommended with ppl who suffer from any probs with the liver, as it contains a chemical that can further impair damage the liver even more! Nice to know-No one told me, and there was never any warning issue anywhere by GSK or the NCI that this kind of problem could/would arise! What the heck???
to vote them Bad, Good or Indifferent....I think I've relayed my opinion. and Thanks for nothing-The "hype of Tykerb" is all just that....Hype..NOT HOPE! -...sorry
F.Perry
Click here to get the FierceBiotech email newsletter for FREE!
Comments (1) | Post a comment